Company Description
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer.
MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Dec 19, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | David M. Urso B.A., Esq., J.D. |
Contact Details
Address: 11455 El Camino Real, Suite 250 San Diego, California 92130 United States | |
| Phone | 858-369-7100 |
| Website | meipharma.com |
Stock Details
| Ticker Symbol | MEIP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001262104 |
| CUSIP Number | 55279B202 |
| ISIN Number | US55279B3015 |
| Employer ID | 51-0407811 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David M. Urso B.A., Esq., J.D. | Chief Executive Officer, President and Director |
| Dr. Richard G. Ghalie M.D., MBA | Chief Medical Officer |
| Justin J. File | Chief Financial Officer and Corporate Secretary |
| Yomara Gomez-Naiden | Senior Vice President of Operations and Quality |
| Nicole Chyoko Iida | Vice President of Legal Affairs |
| Anne Frese | Chief People Officer |
| Dr. Robert D. Mass | Strategic Advisor |
| David A. Walsey J.D., L.L.M. | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2024 | EFFECT | Notice of Effectiveness |
| Feb 28, 2024 | 424B5 | Filing |
| Feb 23, 2024 | UPLOAD | Filing |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 20, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 13, 2024 | 10-Q | Quarterly Report |
| Jan 17, 2024 | 8-K | Current Report |